US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Vigil Neuroscience, Inc. - Common Stock (NQ:VIGL)

8.050 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation ↗
JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Vigil Neuroscience ↗
 
Via Benzinga
News headline image
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 155 companies set new 52-week lows. 
Via Benzinga
News headline image
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
News headline image
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
News headline image
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗
 
Via Benzinga
News headline image
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
Company remains on track to report interim data from Phase 2 trial in the second half of 2023 
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
News headline image
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Vigil Neuroscience to Present at Stifel 2023 CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >